CAJ | 학술논문

目的了解深圳市结核分枝杆菌耐药情况,为深圳市结核病控制提供科学依据.方法依据(WHO/IUALD)结核病耐药指南,将深圳市2005年和2009年每年3月至8月间所有新涂阳和新登记的复治涂阳的肺结核作为监测对象,对2005年802例、2009年1 054例成功分离的结核分枝杆菌菌株,用比例法进行药物敏感实验.结果 2005年总耐药率18.3%,初始耐药率17.2%,获得性耐药率31.3%;总耐多药率4.7%,初始和获得性耐多药率分别为3.25%和21.9%;2009年总耐药率17.4%,初始耐药率16%,获得性耐药率39.3%;总耐多药率3.8%,初始和获得性耐多药率分别为3.02%和16.4%.2009年以上各耐药率、各耐多药率与2005年比较,差异无统计学意义,2005年、2009年的获得性耐药率、获得性耐多药率均显著高于初始耐药率、初始耐多药率.结论深圳市耐药结核病的发生率处于较高水平,应该引起高度重视.
목적 료해심수시결핵분지간균내약정황,위심수시결핵병공제제공과학의거.방법 의거(WHO/IUALD)결핵병내약지남,장심수시2005년화2009년매년3월지8월간소유신도양화신등기적복치도양적폐결핵작위감측대상,대2005년802례、2009년1 054례성공분리적결핵분지간균균주,용비례법진행약물민감실험.결과 2005년총내약솔18.3%,초시내약솔17.2%,획득성내약솔31.3%;총내다약솔4.7%,초시화획득성내다약솔분별위3.25%화21.9%;2009년총내약솔17.4%,초시내약솔16%,획득성내약솔39.3%;총내다약솔3.8%,초시화획득성내다약솔분별위3.02%화16.4%.2009년이상각내약솔、각내다약솔여2005년비교,차이무통계학의의,2005년、2009년적획득성내약솔、획득성내다약솔균현저고우초시내약솔、초시내다약솔.결론 심수시내약결핵병적발생솔처우교고수평,응해인기고도중시.
Objective To understand the situation of drug resistance( DR) and multi-drug resistance( MDRTB) tuberculosis in Shenzhen and provide scientific evidence for TB control in Shenzhen. Methods According to drug resistance TB guidelines issued by WHO/IUALD, all new smear positive cases and.new registered retreatment smear positive cases in 2005 and 2009 were included in the surveillance. A total of 1856 strains of mycobacterium tuberculosis were isolated and drug susceptibility test were performed with the proportional method. Results In 2005, the overall DR rate was 18. 3% , 17. 2% and 31. 3% for initial and acquired DR respectively, overall MDR rate was 4. 74% ,3.25% and 21.9% respectively for initial and acquired MDR. In 2009, the overall DR rate was 17.4% , 16% and 39. 3%for initial and acquired DR respectively,overall MDR rate was 3.8% ,3.02% and 16.4% respectively for initial and acquired MDR. In 2005,2009, the rates of acquired DR and acquired MDR were significantly higher than the rates of initial DR and initial MDR. Conclusion The incidence of TB drug resistance in Shenzhen was high and merits attention.